COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 22Jan2021 at 18:00 as dose 1, single (Lot number: EL9261), in left arm, on 12Feb2021 at 17:30 as dose 2, single (Lot number: EN6201), in left arm, on 27Sep2021 as dose 3 (booster), single (Lot number: 301308A), in left arm and on 01Apr2022 at 09:00 as dose 4 (booster), single (Lot number: FK9894) at the age of 55 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing), notes: other medical history: hypertension; "Asthma" (unspecified if ongoing), notes: other medical history: asthma; "Environmental allergies" (unspecified if ongoing), notes: other medical history: environmental allergies; "Obesity" (unspecified if ongoing), notes: other medical history: obesity; "Migraines" (unspecified if ongoing), notes: other medical history: migraines. Concomitant medication(s) included: IRBESARTAN, start date: 10Jul2019; TURMERIC [CURCUMA LONGA]; VITAMIN D [VITAMIN D NOS]; CETRIZINE; BABY ASPIRIN.  The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 05Jul2022, outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (04Jul2022) Negative, notes:(tested neg 04Jul x 2 and in the morning of 05Jul); (04Jul2022) Negative, notes: (tested neg 04Jul x 2 and in the morning of 05Jul); (05Jul2022) Negative, notes: (tested neg 04Jul x 2 and in the morning of 05Jul); (05Jul2022) Positive, notes: had a positive rapid antigen test by the afternoon of 05Jul; (06Jul2022) Positive, notes: (tested positive on repeat rapids prior to 13Jul); (07Jul2022) Positive, notes: (tested positive on repeat rapids prior to 13Jul); (08Jul2022) Positive, notes: (tested positive on repeat rapids prior to 13Jul); (09Jul2022) Positive, notes: (tested positive on repeat rapids prior to 13Jul); (10Jul2022) Positive, notes: (tested positive on repeat rapids prior to 13Jul); (11Jul2022) Positive, notes: (tested positive on repeat rapids prior to 13Jul); (12Jul2022) Positive, notes: (tested positive on repeat rapids prior to 13Jul); (13Jul2022) Negative, notes: a negative rapid antigen test on 13Jul; (14Jul2022) Negative, notes: had a negative rapid antigen test again on 14Jul; (16Jul2022) Positive, notes: symptoms of congestion and scratchy throat returned on 16Jul, had a positive rapid antigen test that day; (17Jul2022) Positive, notes: cont to have a pos rapid test every day since, symptoms improved by 20Jul although not completely resolved yet; (18Jul2022) Positive, notes: cont to have a pos rapid test every day since, symptoms improved by 20Jul although not completely resolved yet; (19Jul2022) Positive, notes: cont to have a pos rapid test every day since, symptoms improved by 20Jul although not completely resolved yet; (20Jul2022) Positive, notes: cont to have a pos rapid test every day since, symptoms improved by 20Jul although not completely resolved yet. Therapeutic measures were taken as a result of vaccination failure, covid-19.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect drug BNT162B2 to the reported events Vaccination failure and COVID-19 cannot be ruled out.